SEARCH

SEARCH BY CITATION

References

  • 1
    Lavanchy D. The global burden of hepatitis C. Liver Int 2009; 29( Suppl 1): 74-81.
  • 2
    WHO. Global surveillance and control of hepatitis C. Report of a WHO consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999; 6: 35-47.
  • 3
    Bowen DG, Walker CM. The origin of quasispecies: cause or consequence of chronic hepatitis C viral infection? J Hepatol 2005; 42: 408-417.
  • 4
    Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci 2006; 3: 47-52.
  • 5
    Hoofnagle JH. Course and outcome of hepatitis C. HEPATOLOGY 2002; 36: S21-S29.
  • 6
    Brass V, Moradpour D, Blum HE. Molecular virology of hepatitis C virus (HCV): 2006 update. Int J Med Sci 2006; 3: 29-34.
  • 7
    Berenguer M. Management of hepatitis C virus in the transplant patient. Clin Liver Dis 2007; 11: 355-376.
  • 8
    Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965.
  • 9
    Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
  • 10
    Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. PEGinterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-355.
  • 11
    Hézode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360: 1839-1850.
  • 12
    McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360: 1827-1838 and erratum: [Erratum, N Engl J Med 2009;361:1516].
  • 13
    McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhal NH, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010; 362: 1292-1303 and erratum: [Erratum, N Engl J Med 2010;362:1647]..
  • 14
    Jacobson IM, McHutchison JG, Dusheiko GM, DiBisceglie MA, Reddy R, Bzowej NH, et al. Telaprevir in combination with peginterferon and ribavirin in genotype 1 HCV treatment-naïve patients: final results of Phase 3 ADVANCE study [Abstract]. HEPATOLOGY 2010; 52( Suppl 4): 427A.
  • 15
    Foster G, Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, et al. Telaprevir-based therapy in G1 HCV-infected patients with prior null response, partial response or relapse to peginterferon/ribavirin: REALIZE trial final results [Abstract]. Hepatol Int 2011; 5: 14.
  • 16
    Strader DB. Understudied populations with hepatitis C. HEPATOLOGY 2002; 36( Suppl 1): S226-S236.
  • 17
    Terrault NA. Treatment of recurrent hepatitis C in liver transplant recipients. Clin Gastroenterol Hepatol 2005; 3( 10 Suppl 2): S125-S131.
  • 18
    Neoral (Cyclosporine) US Package Insert, 2009. http://www.accessdata. fda.gov/drugsatfda_docs/label/2009/050715s028,050716s029lbl.pdf (accessed 31 January, 2011).
  • 19
    Prograf (Tacrolimus) US Package Insert, 2009. http://www.accessdata. fda.gov/drugsatfda_docs/label/2009/050708s027,050709s021lbl.pdf (accessed 31 January, 2011).
  • 20
    Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T. Human P-glycoprotein transports cyclosporine and FK506. J Biol Chem 1993; 268: 6077-6080.
  • 21
    Wu CY, Benet LZ. Disposition of tacrolimus in isolated perfused rat liver: influence of troleandomycin, cyclosporine, and GG918. Drug Metab Dispos 2003; 31: 1292-1295.
  • 22
    Van Heeswijk R, Gysen V, Boogaerts G, de Paepe E, Vangeneugen T, de Backer K, et al. The pharmacokinetic (PK) interaction between tenofovir disoproxil fumarate (TDF) and the investigational HCV protease inhibitor telaprevir (TVR) [Abstract]. 48th International Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2008); A-966.
  • 23
    Krishna R, Bergman A, Larson P, Cote J, Lasseter K, Dilzer S, et al. Effect of a single cyclosporine dose on the single-dose pharmacokinetics of sitagliptin (MK-0431), a dipeptidyl peptidase-4 inhibitor, in healthy male subjects. J Clin Pharmacol 2007; 47: 165-174.
  • 24
    Dowell JA, Stogniew M, Kraue D, Henkel T, Damle B. Lack of pharmacokinetic interaction between anidulafungin and tacrolimus. J Clin Pharmacol 2007; 47: 305-314.
  • 25
    Frassetto LA, Browne M, Cheng A, Wolfe AR, Roland ME, Stock PG, et al. Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients. Am J Transplant 2007; 7: 2816-2820.
  • 26
    Teicher E, Vincent I, Bonhomme-Faivre L, Abbara C, Barrail A, Boissonnas A, et al. Effect of highly active antiretroviral therapy on tacrolimus pharmacokinetics in hepatitis C virus and HIV co-infected liver transplant recipients in the ANRS HC-08 study. Clin Pharmacokinet 2007; 46: 941-952.
  • 27
    Vogel M, Voigt E, Michaelis HC, Sudhop T, Wolff M, Türler A, et al. Management of drug-to-drug interactions between cyclosporine A and the protease-inhibitor lopinavir/ritonavir in liver-transplanted HIV-infected patients. Liver Transpl 2004; 10: 939-944.
  • 28
    Garg V, Luo X, van Heeswijk R, Kauffman RS. The effect of low-dose ritonavir on the pharmacokinetics of the investigational HCV protease inhibitor telaprevir in healthy volunteers. Poster: Conference on Retroviruses and Opportunistic Infections. Feb 28, 2011.
  • 29
    Hesselink DA, van Schaik RH, van der Heiden IP, van der Werf M, Gregoor PJ, Lindemans J, et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003; 74: 245-254.
  • 30
    Grimm SW, Einolf HJ, Hall SD, He K, Lim HK, Ling KH, et al. The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the pharmaceutical research and manufacturers of America. Drug Metab Dispos 2009; 37: 1355-1370.